No abstract available
Keywords:
disability; frailty; prevention; sarcopenia.
PubMed Disclaimer
Conflict of interest statement
Conflict of interest: All the authors are investigators of the SPRINTT project, an Innovative Medicines Initiative (IMI)-funded project (including partners from the European Federation of Pharmaceutical Industries and Aassociations [EFPIA]). Matteo Cesari has received honoraria for presentations at scientific meetings and/or research fundings from Nestlé, Pfizer, Novartis. Bruno Vellas has served as consultant/advisor for Biogen, GSK, Lilly, Lundbeck, Medivation, MSD, Nestlé, Nutricia, Pfizer, Roche, Sanofi, Servier, TauRx Therapeutics, Novartis.
References
-
-
Vellas B, Cestac P, Morley JE. Implementing frailty into clinical practice: we cannot wait. J Nutr Health Aging. 2012;16:599–600.
-
PubMed
-
-
Clegg A, Young J, Iliffe S, Rikkert MO, Rockwood K. Frailty in elderly people. Lancet. 2013;381:752–762.
-
PMC
-
PubMed
-
-
Morley JE, Vellas B, Abellan van Kan G, et al. Frailty consensus: a call to action. J Am Med Dir Assoc. 2013;14:392–397.
-
PMC
-
PubMed
-
-
Cesari M, Landi F, Vellas B, Bernabei R, Marzetti E. Sarcopenia and physical frailty: two sides of the same coin. Front Aging Neurosci. 2014;6:192.
-
PMC
-
PubMed